Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up one-third of Viatris' total sales. The remaining sales are derived from its portfolio of legacy products, including Lipitor, Norvasc, Lyrica, and Viagra.
Last trade$20.56
Day change-$0.185 (-0.89%)
Day range$20.41 – $20.92
Volume3,287,650
Market cap$23.78B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$23.78B
Price / earnings
—
Price / book
1.74×
Price / sales
1.61×
EV / sales
2.4×
EV / EBITDA
12.09×
Profitability
Earnings per share
-$0.53
Return on assets
-1.75%
Return on equity
-4.44%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.97×
Current ratio
1.55×
Quick ratio
0.97×
Cash ratio
0.27×
Cash flow
Price / cash flow
9.57×
Price / free cash flow
11.27×
Free cash flow
$2.11B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for VTRS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$3.75B
$3.76B
$3.52B
$3.7B
$3.76B
$3.58B
$3.25B
$3.53B
Cost of revenue
$2.31B
$2.3B
$2.36B
$2.56B
$2.39B
$2.25B
$2.09B
$2.31B
Gross profit
$1.44B
$1.46B
$1.16B
$1.15B
$1.37B
$1.33B
$1.16B
$1.22B
Selling, general and administrative
$950.8M
$1.13B
$928.8M
$1.03B
$886.6M
$928.7M
$948.1M
$1.05B
Research and development
$231.7M
$242.5M
$248.6M
$323M
$250.4M
$218.8M
$222M
$234.8M
Total operating expenses
$1.18B
$1.45B
$1.24B
$1.34B
$1.19B
$1.1B
$4.04B
$1.39B
Operating income
$261.5M
$6.3M
-$79.7M
-$192.7M
$178.8M
$233M
-$2.88B
-$179.8M
Interest expense
-$112.4M
-$120.7M
-$120.1M
-$119.6M
-$119.6M
-$116.6M
-$115.5M
-$120.2M
Income before taxes
$127.9M
-$64M
-$247.3M
-$343M
-$7.9M
-$217.1M
-$3.1B
-$526.5M
Income taxes
$453.2M
$54.8M
-$423.7M
-$2.9M
$120.3M
-$212.5M
-$55M
-$10M
Net income
-$325.3M
-$118.8M
$176.4M
-$340.1M
-$128.2M
-$4.6M
-$3.04B
-$516.5M
Net income attributable to common shareholders
-$325.3M
-$118.8M
$176.4M
-$340.1M
-$128.2M
-$4.6M
-$3.04B
-$516.5M
EBITDA
$947.7M
$751.8M
$649.9M
$571M
$923M
$863.7M
$645.8M
$678M
Basic earnings per share
-$0.28
-$0.10
$0.15
-$0.29
-$0.11
$0.00
-$2.55
-$0.43
Diluted earnings per share
-$0.28
-$0.10
$0.15
-$0.29
-$0.11
$0.00
-$2.55
-$0.44
Recent news
Company coverage with links to the original publishers.
A comparison of two Medical Services stocks reveals that Viatris (VTRS) presents a better value opportunity than Danaher (DHR). VTRS has a Zacks Rank of #2 (Buy) with improving earnings outlook and superior valuation metrics, including a forward P/E of 7.98 versus DHR's 27.39, and a Value grade of A compared to DHR's C.
Opus Genetics announced completion of dosing in Cohort 2 of its OPGx-BEST1 Phase 1/2 trial with data expected in Q1 2027. The company also reported full enrollment of its OPGx-LCA5 Phase 3 registrational trial with dosing to begin in Q4 2026, FDA clearance for OPGx-RDH12, and FDA approval of phentolamine ophthalmic solution for presbyopia. With $89 million in cash, the company projects runway into 2029.
Viatris reported Q3 2026 revenue of $3.75 billion, down 0.3% year-over-year and slightly missing consensus estimates by 0.76%. However, the company delivered a strong EPS beat of 10.94%, reporting $0.71 versus the expected $0.64. Regional performance was mixed, with Greater China showing strong growth of 14.2%, while Emerging Markets Generics declined sharply by 36.5%. The stock has outperformed the broader market with a 9.9% return over the past month and currently holds a Zacks Rank #3 (Hold) rating.
Viatris (VTRS) beat Q3 adjusted EPS expectations at 71 cents versus 64 cents consensus, driven by margin expansion and strong Greater China sales growth of 14.2%. However, total revenues of $3.75 billion missed estimates and declined 0.3% year-over-year due to supply disruptions in Europe and Emerging Markets. The company raised full-year 2026 adjusted EPS guidance to $2.56-$2.63, though manufacturing suspension at its Nashik facility threatens Q4 revenues with an estimated $100 million impact.
Viatris (VTRS) is expected to report Q3 2026 revenues of $3.78 billion and earnings of 64 cents per share, likely beating consensus estimates. The company faces headwinds from FDA import alerts affecting 11 products, supply disruptions, and competitive pressures, but these are expected to be offset by new product growth and strength in branded markets, particularly in Greater China and Emerging Markets.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.12 per share
Declared
Nov 2, 2026
Ex-dividend
Nov 23, 2026
Pay date
Dec 16, 2026
Ex-dividend
Amount / share
Pay date
Type
Aug 21, 2026
$0.12
Sep 16, 2026
recurring
May 22, 2026
$0.12
Jun 17, 2026
recurring
Mar 9, 2026
$0.12
Mar 18, 2026
recurring
Nov 24, 2025
$0.12
Dec 15, 2025
recurring
Aug 22, 2025
$0.12
Sep 15, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.